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Objectives. We examined the mRNA expression and protein
localization of inducible nitric oxide synthase (iNOS) and tumor
necrosis factor-alpha (TNF-alpha) in myocardial tissue obtained
from patients with dilated cardiomyopathy (DCM).
Background. The etiology of DCM is unknown, but viral
infection or autoimmune abnormalities that induce cytokine
expression have been proposed as pathogenetic factors. Nitric
oxide (NO), synthesized by nitric oxide synthase (NOS), has
negative inotropic and cytotoxic effects on cardiomyocytes. Cyto-
kines such as TNF-alpha are potent stimulators of iNOS expres-
sion. Expression of iNOS leads to excessive production of NO in
the myocardium and may modulate cardiac contractility and
ventricular morphology.
Methods. We examined the mRNA expression and protein
localization of iNOS and TNF-alpha in myocardial tissue obtained
from 24 patients with DCM, 20 patients with hypertrophic car-
diomyopathy (HCM) and 15 control subjects, using the reverse
transcriptase-polymerase chain reaction method and immunohis-
tochemical studies. We then compared the differences in clinical
characteristics between DCM patient subgroups with and without
myocardial iNOS expression.
Results. Messenger RNA expression of iNOS and TNF-alpha
was observed, respectively, in 13 (54%) and 18 (75%) patients with
DCM. Gene expression of TNF-alpha was consistently detected in
endomyocardial tissue from patients with DCM and INOS expres-
sion. Inducible NOS protein was evident only in cardiomyocytes,
whereas TNF-alpha was apparent in both cardiomyocytes and
endomyocardial endothelium. Neither mRNA expression nor pro-
tein localization of iNOS or TNF-alpha was observed in cardiac
tissue obtained from patients with HCM or control subjects.
Patients with DCM and iNOS mRNA showed a lower left ventric-
ular ejection fraction (p < 0.01) and a higher left ventricular
volume (p < 0.05) than the negative DCM group.
Conclusions. Inducible NOS was consistently coexpressed with
TNF-alpha in myocardial tissue obtained from a subgroup of
patients with DCM and advanced left ventricular dysfunction.
(J Am Coll Cardiol 1997;29:716–24)
q1997 by the American College of Cardiology
Nitric oxide is produced from the terminal guanidino nitrogen
atom of L-arginine by the nitric oxide synthase (NOS) family
of enzymes. There are two types of NOS: constitutive,
Ca21/calmodulin-dependent NOS and Ca21/calmodulin-
independent NOS, the latter being induced by a number of
inflammatory cytokines. Cytokines, such as interleukin-1beta
and tumor necrosis factor-alpha (TNF-alpha) have been shown
to cause expression of iNOS in cardiomyocytes obtained from
animals (1–3). Recent studies (4–6) have suggested that
generation of nitric oxide (NO) in the endocardium and
myocardium regulates cardiac function in a paracrine and
autocrine fashion. Depressed myocardial contractility in ani-
mals and humans occurs in conditions associated with elevated
plasma levels of cytokines, such as septic shock (7). It has been
suggested (8,9) that profound cardiac dysfunction can be
attributed to excessive NO production resulting from cytokine-
induced expression of iNOS in myocardial and vascular tissues.
De Belder et al. (10) observed an increase in the enzyme
activity of Ca21-independent NOS, but not Ca21-dependent
NOS, in the myocardium of patients with DCM. However, it is
not clear whether iNOS activity in myocardial tissue in patients
with DCM is directly reflected by mRNA expression, and the
relation between expression of iNOS and cytokines has not
been clarified. We used the polymerase chain reaction (PCR)
method to examine the mRNA expression of iNOS and
TNF-alpha in endomyocardial biopsies obtained from patients
with DCM or HCM and control subjects. The localization of
iNOS and the cytokine protein in the myocardial tissue was
also studied by immunohistochemical analysis. Furthermore,
we explored the differences in clinical characteristics and
prognosis between the DCM patient subgroups with and
without myocardial iNOS.
Methods
Subjects. We examined endomyocardial biopsies obtained
from 24 patients with DCM, 20 patients with HCM and 15
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control subjects. The DCM group included 19 men and 5
women (mean age 58 years, range 19 to 76). In terms of the
clinical severity of congestive heart failure, 3 patients were in
New York Heart Association functional class I; 16 were in class
II; and 5 were in class III. The mean 6 SD values for left
ventricular ejection fraction and cardiac index were 31 6 9%
and 2.8 6 0.8 liter/min per m2, respectively.
Digitalis and diuretic drugs, including furosemide and
spironolactone, were administered orally in 22 and 21 patients,
respectively. Seven of the 24 patients were treated with a
beta-adrenergic blocking agent, and 5 received nitroglycerin
(Table 1). The HCM group included 14 men and 6 women
(mean age 48 years, range 20 to 65). They had no significant
systolic ventricular function and no signs or symptoms of heart
failure. Dilated cardiomyopathy and HCM were diagnosed
according to the criteria of the World Health Organization/
International Society and Federation of Cardiology Task Force
(11). Patients were excluded if there was any angiographic
evidence of coronary heart disease, ischemic changes during
exercise testing, systemic hypertension, concomitant systemic
or ventricular function or excessive alcohol consumption. A
subject group with myocardial disorder suspected on the basis
of premature beats and minor echocardiographic abnormali-
ties underwent endomyocardial biopsy. Neither the resulting
pathologic findings nor close clinical examination showed
evidence of myocardial disease, and these subjects were des-
ignated as the control group with normal cardiac function and
morphology. None of the patients or control subjects had any
medical history of serious infectious illness (i.e., pneumonia,
sepsis or myocarditis). The study protocol was approved by our
hospital ethics committee, and written informed consent was
obtained from all subjects.
Myocardial tissue samples. Five right ventricular endo-
myocardial biopsies were obtained from each subject with a
bioptome (Type A, Yufu Corp., Tokyo, Japan) by the femoral
vein approach. Four tissue samples were fixed in 10% formalin,
embedded in paraffin and cut into 4-mm sections. Each section
was stained with hematoxylin and eosin and was also used for
Abbreviations and Acronyms
DCM 5 dilated cardiomyopathy
HCM 5 hypertrophic cardiomyopathy
IL 5 interleukin
iNOS 5 inducible nitric oxide synthase
NO 5 nitric oxide
NOS 5 nitric oxide synthase
PCR 5 polymerase chain reaction
SSC 5 sodium citrate/sodium chloride
TNF-alpha 5 tumor necrosis factor-alpha
Table 1. Clinical Characteristics and Results of Reverse Transcriptase-Polymerase Chain Reaction and Immunohistochemical Analysis in 24
Patients With Dilated Cardiomyopathy
Pt
No.
Age (yr)/
Gender NYHA
Treatment
LVEF
(%)
PCWP
(mm Hg)
CI
(liter/min per m2)
PCR Result Immunohist
ACEI BB iNOS TNF-Alpha iNOS TNF-Alpha
1 19/M I 1 1 37 10 3.4 2 2 2 2
2 28/M I 2 1 46 8 2.4 2 1 2 2
3 37/M II 2 2 44 9 4.7 2 2 2 2
4 41/M III 1 2 33 8 2.5 2 1 2 1
5 43/M III 1 2 13 15 3.8 1 1 1 1
6 52/M III 1 2 27 11 2.8 2 1 2 2
7 54/M II 2 2 43 16 2.5 2 1 2 1
8 54/M III 2 2 43 16 2.5 2 1 2 1
9 57/M II 2 2 28 8 3.3 1 1 2 2
10 60/M II 2 2 45 2 2.0 2 2 2 2
11 60/M II 2 2 24 14 4.0 1 1 2 2
12 61/M II 2 1 35 4 2.0 1 1 1 1
13 65/M II 2 2 31 6 2.0 1 1 1 1
14 66/M II 2 2 19 16 2.2 1 1 1 1
15 69/M III 1 2 30 6 2.6 1 1 1 1
16 69/M II 2 2 22 3 2.9 1 1 1 1
17 70/M II 1 1 17 7 3.6 2 2 2 2
18 73/M II 1 1 23 9 3.7 1 1 1 1
19 75/M II 1 2 36 13 2.1 2 2 2 2
20 64/F II 1 1 22 11 2.1 1 1 2 1
21 67/F II 2 2 30 7 2.2 1 1 2 2
22 68/F II 2 2 32 20 2.5 2 2 2 2
23 73/F II 1 1 30 12 2.9 1 1 1 2
24 76/F I 1 2 39 13 2.9 1 1 2 1
ACEI 5 angiotensin-converting enzyme inhibitor; BB 5 beta-blocker; CI 5 cardiac index; F 5 female; Immunohist 5 immunohistochemical analysis; iNOS 5
inducible nitric oxide synthase; LVEF 5 left ventricular ejection fraction; M 5 male; NYHA 5 New York Heart Association functional class; PCWP 5 pulmonary
capillary wedge pressure; Pt 5 patient; TNF-Alpha 5 tumor necrosis factor-alpha; 1 5 positive; 2 5 negative.
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immunohistochemical analysis. The remaining tissue was im-
mediately frozen at 2808C and used for reverse transcriptase-
PCR analysis.
Positive control cells for iNOS and TNF-alpha mRNA.
Human aortic vascular smooth muscle cells were isolated from
an aortic medial layer (Kurabou Corp., Osaka, Japan) and
seeded in culture flasks (Becton) in a humidified atmosphere
of 5% CO2–95% air at 378C. The culture medium (RPMI-
1640, Gibco) was changed every 3 days. The cells reached
confluence after 7 days, after which the medium was replaced
with fresh medium containing IL-1beta (10 ng/ml), and the
cultured vascular smooth muscle cells were incubated for 6 to
48 h. For measurement of concentrations of nitrite and nitrate,
the final products of liberated NO, the culture medium was
measured by mixing 500 ml of medium with an equal volume of
Griess reagent. Absorbance at 550 nm was measured, and
nitrite and nitrate concentrations were determined using a
curve calibrated from sodium nitrite standards. Vascular
smooth muscle cells in which significant NO production was
confirmed by an increase in nitrite and nitrate levels were used
as positive control cells for detection of iNOS mRNA.
Peripheral blood monocytes were prepared from normal
blood donors. After centrifugation, the monocytes were
washed and resuspended in AIM-R medium (Gibco) supple-
mented with 2 mg of anti-human LeuTM-4 (CD3) (Becton
Dickinson). The monocytes were allowed to adhere to the
tissue culture flasks for 48 h at 378C in a humidified atmo-
sphere of 5% CO2–95% air. They were then used as positive
control cells for the detection of TNF-alpha and beta-actin
expression.
Preparation of total RNA. After the endomyocardial tis-
sues and cultured positive control cells were homogenized in a
denaturing solution of guanidium thiocyanate, total RNA was
extracted with phenolchloroform and recovered with isopro-
panol (12). The purity of the extracted RNA was estimated by
determining the ratio of absorbance at 260 nm to that at
280 nm. The RNA extract was diluted to 200 ng/ml with
double-distilled water.
Oligonucleotides. The following PCR primers were used to
amplify cDNA: for iNOS (13): sense, 59-CGG TGC TGT ATT
TCC TTA CGA GGC GAA GAA GG-39 and anti-sense,
59-GGT GCT ACT TGT TAG GAG GTC AAG TAA AGG
GC-39; for TNF-alpha (14): sense, 59-GCC TGT AGC CCA
TGT TGT AG-39 and anti-sense, 59-AAT GAT CCC AAA
GTA GAC CTG CCC-39; and for beta-actin (15): sense,
59-CCT GGC ACC CAG CAC AAT GA-39; and anti-sense,
59-TTG GGA AGG TTG GAT GTT CG-39. The probes used
for Southern blot hybridization were for iNOS: 59-AGG CCC
TGT GAC CTC AGA TAA TCG AGA GCT GGC TCC ATC
CTT AAG TTC TGT GCC GGC AGC-39; for TNF-alpha:
59-TTT GCG GTG GAC GAT GGA GGG GCC GGA ATA
GTA ATA CTC CTG CTT GCT GAT CCA CAT CTG-39;
and for beta-actin: 59-TTT GCG GTG GAC GAT GGA GGG
GCC GGA ATA GTA ATA CTC CTG CTT GCT GAT CCA
CAT CTG-39.
Polymerase chain reaction procedure. Reverse transcriptase-
PCR was performed with a RNA-PCR kit (GeneAmp, Perkin
Elmer-Cetus Corp.). The cDNA was synthesized from 200 ng
of total RNA by reverse transcription at 428C for 30 min using
random hexamers and then amplified with 45 cycles of PCR
using a temperature cycler (Hybain, Middlesex, UK). Polymer-
ase chain reaction amplification of cDNA was performed as
follows: denaturation for 1 min at 948C, followed by 45 cycles
of denaturation for 948C at 30 s, annealing for 1 min at 558C,
extension for 1 min at 728C and final extension for 5 min at
728C.
Southern blot hybridization. Polymerase chain reaction
products (10 ml) were electrophoresed on a 3% NuSieve/1%
Seakem agarose gel (FMC Bioproducts). The DNA bands
were denatured and transferred onto a nylon membrane
(Hybond-N, Amersham, UK) using 0.4 mol/liter of NaOH as
the denaturing buffer and 203 sodium citrate/sodium chloride
(SSC) (0.3 mol/liter NaCl and 0.03 mol/liter sodium citrate at
pH 7.0) as the transferring buffer. The DNA bands were fixed
on the membrane by an ultraviolet linker (Spectromics). The
membrane was then prehybridized in a solution of 50 mmol/
liter Tris-HCl, 1 mol/liter NaCl, 10% dextran sulfate, 1%
sodium dodecyl sulfate and sheared salmon sperm DNA at
658C for 2 h. Hybridization was performed in the same solution
with a [32P]-59-end-labeled probe prepared with a kit (Mega-
label, Takara, Kyoto, Japan). After incubation for 16 h at 658C,
the membrane was washed three times at room temperature
for 10 min and then twice at 658C for 10 min in 2 3 SSC
containing 0.1% sodium dodecyl sulfate. The membrane was
then autoradiographed at 2808C for 24 h.
Immunohistochemical analysis. Immunohistochemical
analysis was performed on paraffin sections to examine the
source of iNOS and TNF-alpha protein production. Anti-mac
NOS (Tranduction Laboratories) and anti-human TNF-alpha
(Genzyme Corp.) were used as primary antibody. To test for
nonspecific staining by the secondary antibody, distilled water
was substituted for the primary antibody on control sections
from patients with DCM.
The tissue sections were deparaffined by xylene and rehy-
drated in 95% ethanol. Endogenous peroxidase activity was
quenched in 2% H2O2 in 60% methanol for 30 min. The tissue
sections were washed for 20 min in phosphate-buffered saline
(pH5 7.4). The appropriate normal serum was applied to each
section for 20 min. The excess serum was then blotted off; the
primary antibody was added; and the sections were left for 8 h
at 48C. All primary antibodies were diluted in phosphate-
buffered saline. The sections were washed three times in the
buffer, incubated with biotinylated secondary antibody for
10 min and washed in the buffer and then incubated with a
peroxidase conjugated avidin-biotin complex (Histofine
SAB-PO kit, Nichiren Corp., Tokyo, Japan) for 5 min. The
sections were washed three times in phosphate-buffered saline.
Diaminobenzidine tetrahydrochloride was used as chromogen
to visualize the presence and distribution of iNOS and TNF-
alpha.
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Morphometric evaluation. Morphometric investigation
was performed on paraffin sections. These were measured
using a microscope equipped with a 340 objective and 310
ocular lesions in which a micrometer was settled. Hematoxylin
and eosin-stained sections were used for measurement of the
fiber diameters and inflammatory cellular infiltrates. The di-
ameter was evaluated on cross sections of myofibers in the
nuclear region. Thirty profiles were measured in each case, and
the results were expressed as mean value and standard devia-
tion. The number of inflammatory cellular infiltrates (infiltra-
tion of macrophage, lymphocyte and pan-leukocyte) into myo-
cardial tissue per field was counted in randomly selected fields
(n5 30). The degree of interstitial fibrosis was evaluated using
an image analyzer (IBAS-2000, Zeiss, Oberkochen, Germany).
The ratio of fibrotic area to total myocardial area was mea-
sured on Azan-stained section.
Plasma TNF-alpha concentration. Plasma levels of TNF-
alpha in patients with DCM were determined by using a
commercially available enzyme-linked immunosorbent assay
kit (TNF-EASI, Medgemix, Fleurus, Belgium). Blood samples
were obtained from the femoral vein at the time of endomyo-
cardial biopsy and immediately centrifuged and stored at
2808C until assayed. The plasma level in age-matched healthy
subjects was ,5 pg/ml (n 5 10).
Statistical analysis. Results are expressed as mean value6
SD. Differences between groups of patients with or without
iNOS expression were analyzed by unpaired t test. Results
were considered statistically significant at p , 0.05.
Results
Positive control cells. Interleukin-1beta stimulated nitrite
and nitrate production from cultured vascular smooth muscle
cells in a time-dependent manner. Nitrite and nitrate in the
cultured medium increased from 1.7 mmol/liter at 6 h to 3.0
mmol/liter at 12 h, 3.9 mmol/liter at 24 h and 4.1 mmol/liter at
48 h. Reverse transcriptase-PCR revealed a single band corre-
sponding to the size of iNOS cDNA (257 base pairs) after
stimulation with IL-1beta (Fig. 1a). Tumor necrosis factor-
alpha and beta-actin mRNA were expressed in cultured mono-
cytes (Fig. 1b).
Messenger RNA expression. Expression of iNOS mRNA
was detected in 13 (54%) of the 24 patients with DCM,
whereas expression of TNF-alpha mRNA was detected in 18
(75%) (Fig. 2, Table 1). TNF-alpha mRNA was coexpressed
with iNOS mRNA in all 13 patients with iNOS expression
(Table 1). Expression of iNOS mRNA alone was not observed
in any of the myocardial specimens. TNF-alpha mRNA was
detected in five biopsy specimens without iNOS coexpression.
Southern blot hybridization confirmed the presence of both
iNOS and TNF-alpha in the PCR product. Neither myocardial
iNOS mRNA nor TNF-alpha mRNA was expressed in any
of the 20 patients with HCM or the 15 control subjects (Fig. 3
and 4).
Immunohistochemical analysis. Immunohistochemical
analysis was performed to identify the source of iNOS and
TNF-alpha protein in the myocardial tissue. Immunostaining
of iNOS protein was localized to abundant cardiac myocytes in
the subendocardium and was distributed patchily and evenly
on cytoplasm of myocytes in eight patients with DCM (Fig. 5a).
Figure 1. a, Reverse transcriptase-PCR and Southern blot hybridiza-
tion show the expression of iNOS mRNA in human vascular smooth
muscle cells. The vascular smooth muscle cells were incubated with
IL-1beta for 48 h and amplified with cDNA for use as an iNOS probe.
b, Reverse transcriptase-PCR and Southern blot hybridization show
the expression of TNF-alpha in cultured human monocytes. The
monocytes were incubated with CD3 for 48 h, amplified with 528- and
438-base pair (bp) cDNA and hybridized with cDNA for use as
beta-actin and TNF-alpha probes. SM 5 size marker.
Figure 2. Reverse transcriptase-PCR of iNOS (a) and TNF-alpha (b)
mRNA in endomyocardial biopsies from 24 patients with DCM.
Inducible NOS mRNA was expressed in 13, and TNF-alpha mRNA in
18, of the 24 patients. bp 5 base pair; P 5 positive control cells; SM 5
size marker.
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Inducible NOS immunostaining was consistently detected in
the myocardial tissue obtained from patients with DCM who
showed positive myocardial iNOS mRNA (Table 1). In seven
of eight patients with DCM in whom myocardial iNOS protein
was positive, myocardial TNF-alpha was concomitantly present
(Table 1). Tumor necrosis factor-alpha immunostaining was
localized not only in cardiac myocytes but also in endomyocar-
dial endothelium (Fig. 5c). This pattern was observed consis-
tently in 12 biopsy tissues from patients with DCMwho showed
positive myocardial TNF-alpha protein. All these samples
expressed TNF-alpha mRNA. No significant immunostaining
was observed in the infiltrating macrophages or lymphocytes in
the myocardium. Testing for nonspecific staining by the sec-
ondary antibody alone was carried out on control sections from
patients with DCM. Figure 5, b and d, shows an absence of
nonspecific myocardial immunostaining with secondary anti-
body alone in the myocardial tissue obtained from patients
with DCM. Neither iNOS nor TNF-alpha immunostaining was
present in any of the specimens from the HCM or control
groups.
Morphometric analysis. All the endomyocardial biopsy
samples were subjected to histomorphometric evaluation. Al-
though cellular infiltration was seen in myocardial tissue from
some of the patients with DCM, there was no evidence, such as
myocytic necrosis or a significant amount of cellular infiltra-
tion, to suggestive active myocarditis. There were no differ-
ences in histomorphometric features between the iNOS-
positive and iNOS-negative groups (Table 2).
Plasma TNF-alpha concentration. Plasma TNF-alpha lev-
els in the patients with DCM ranged from 2.1 to 77.5 pg/ml
(mean 6 SD 19.1 6 18.5). This was significantly higher than in
healthy subjects. There was no significant difference between
TNF-alpha mRNA-positive and -negative patients (21.1 6 9.9
vs. 17.3 6 4.0 pg/ml, p 5 0.71).
Clinical data. As shown in Table 3, several factors differed
between the two groups. In the myocardial iNOS-positive
patient subgroup, left ventricular end-systolic diameter was
significantly enlarged (576 7 vs. 506 7 mm, p, 0.05), and left
ventricular ejection fraction was reduced (27 6 7% vs. 37 6
9%, p , 0.01). However, when the patients with DCM were
classified according to the presence or absence of myocardial
TNF-alpha mRNA, no significant differences were observed
(left ventricular ejection fraction 29.9 6 8.9% vs. 35.2 6
10.2%; left ventricular systolic diameter 54.3 6 7.3 vs. 53.0 6
8.3 mm).
Eight cardiac events defined as cardiac-related death, pul-
monary congestion, ventricular tachycardia and sudden death
occurred within the mean follow-up period of 23 6 8 months
in the iNOS-positive group (61%): Six patients had pulmonary
congestion; one had ventricular tachycardia; and one died of
cardiac-related causes. Two cardiac events occurred within the
mean follow-up period of 28 6 8 months in the iNOS-negative
group (18%), both consisting of pulmonary congestion.
Figure 3. Reverse transcriptase-PCR of iNOS (a) and TNF-alpha (b)
mRNA in endomyocardial biopsies from 20 patients with HCM. As
shown, no expression of iNOS and TNF-alpha mRNA was detected in
these samples. PC 5 positive control cells; other abbreviations as in
Figure 1.
Figure 4. Reverse transcriptase-PCR of iNOS (a) and TNF-alpha (b)
mRNA in endomyocardial biopsies from 15 control subjects. No
significant expression of iNOS and TNF-alpha mRNA was found.
Abbreviations as in Figure 3.
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Discussion
Dilated cardiomyopathy is defined as primary cardiac fail-
ure in the absence of coronary, valvular, congenital or pericar-
dial disease. It is characterized by dilation of the left ventricle,
either alone or in association with right ventricular dilation,
and impaired systolic function (11). Bowles et al. (16) have
suggested that persistent or recurrent viral infection is an
etiologic factor in DCM. Subsequent studies (17–20) have
detected viral genomes in endomyocardial biopsies in 10% to
53% of patients with DCM. Recent studies (21,22) suggest the
involvement of an immune dysfunction in the pathogenesis of
myocytic damage in DCM. Cytokines such as IL-1beta,
interleukin-6 and TNF-alpha induced by viral replication and
autoimmune mechanisms have also been proposed as patho-
genetic factors (23–25). Tumor necrosis factor-alpha is consid-
ered a representative cytokine that strongly induces cellular
cytotoxicity, cachexia, fever and shock (26–28). However, the
mechanism of cytokine-mediated progression of ventricular
dysfunction has not been clarified.
Relation between TNF-alpha and iNOS. In the present
study, iNOS mRNA was consistently expressed together with
TNF-alpha mRNA in the myocardial biopsies obtained from
13 patients with DCM. Immunohistochemical analysis demon-
strated that the protein biosynthesis of iNOS and TNF-alpha
was concomitantly observed in cardiac myocytes. In accor-
dance with these observations, Habib et al. (29) recently
reported expression of iNOS protein with a high prevalence of
TNF-alpha protein expression in cardiac myocytes associated
Table 2. Histomorphometric Endomyocardial Biopsy Results
iNOS (mean 6 SD)
p
Value
Positive
(n 5 13)
Negative
(n 5 11)
Myocyte diameter (mm) 23.36 4.7 25.0 6 7.7 0.52
Extent of interstitial fibrosis (%) 29.96 13.7 29.1 6 10.1 0.87
Inflammatory cellular infiltrate
(1/mm2)
2.1 6 1.8 1.8 6 2.6 0.77
iNOS 5 inducible nitric oxide synthase.
Figure 5. Immunohistochemical analysis of iNOS and TNF-alpha in
endomyocardial tissues obtained from patients with DCM (3250,
reduced by 5%). a and c, Detection of iNOS and TNF-alpha proteins
with primary and secondary antibodies. Inducible NOS protein was
located in the cardiomyocytes (a) (arrows), whereas TNF-alpha pro-
tein was also present in endomyocardial endothelium (c) (arrow-
heads). b and d, Results obtained with secondary antibody alone:
There was no evidence of nonspecific immunostaining of the secondary
antibody in the endomyocardial tissue from patients with DCM.
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with DCM. These observations suggest that expression may be
closely related to the cytokine in cardiac tissue and that NO
may be synthesized by myocardial iNOS. Recent studies (2,3)
have shown that cytokines, including TNF-alpha, induce ex-
pression of iNOS mRNA and increase NO production in
cultured rat cardiocytes. Tumor necrosis factor-alpha has been
reported (30) as increasing intracellular levels of tetrahydro-
biopterin synthase, which acts as a cofactor in the enhance-
ment of iNOS mRNA and the production of NO. Further-
more, Balligand et al. (31) reported that adult rat ventricular
myocytes expressed iNOS significantly after exposure to cyto-
kines such as IL-1beta and TNF-alpha and that a contractile
response to isoproterenol in adult rat ventricular myocytes was
depressed after pretreatment with these cytokines. These
findings suggest that TNF-alpha is a factor in the production of
NO in the myocardium and may be involved in the regulation
of cardiac function.
Inducible NOS and myocardium. The expression of iNOS
mRNA was observed in .50% of our patients with DCM.
Haywood et al. (32) similarly observed a slightly higher fre-
quency of myocardial iNOS mRNA expression in patients with
DCM and ischemic heart disease. However, Thoenes et al. (33)
used immunoblot analysis to detect iNOS protein expression
with a consecutive increase in cyclic guanosine monophosphate
in autopsy samples from septic failing heart but not in failing
explanted hearts from patients with DCM. These differences
may be due to the small patient numbers in the respective
studies, the heterogeneity of the patients’ clinical backgrounds
or the different sources of myocardial samples (endomyocar-
dial biopsy vs. explanted heart), as well as the methodology
used (PCR vs. immunoblot analysis).
In humans with left ventricular dysfunction, inhibition of
NO production within the heart enhanced the positive inotrop-
ic action of beta-adrenergic stimulation (34). Furthermore,
Studer et al. (35) recently found a close correlation between
myocardial iNOS gene expression and cardiac diastolic func-
tion in an isolated ventricular muscle strip preparation ob-
tained from human subjects with dilated and ischemic cardio-
myopathy. Inducible NOS has a potent and long-lasting effect
on NO generation, and NO has cytotoxic effects by virtue of its
ability to inhibit mitochondrial respiration (36,37) and to
trigger apoptosis (38–40). It may therefore be speculated that
the acceleration in NO production due to cytokine-induced
iNOS in the myocardium may not only depress cardiac func-
tion but also conspire to bring about myocardial degeneration
or cell death.
Tumor necrosis factor-alpha and myocardium. Torre-
Amione et al. (41) have suggested that the heart itself may be
a major source of secretion and target for TNF-alpha in
patients with end-stage heart failure due to dilated and isch-
emic cardiomyopathy. Their study may be consistent with our
findings, although our patients showed a higher positive per-
centage of myocardial TNF-alpha mRNA expression and
additional distribution of TNF-alpha protein in endocardial
endothelium. Kapadia et al. (42) showed that endotoxin-
stimulated feline cardiac myocytes express TNF-alpha mRNA
and synthesize biologically active TNF-alpha. Yokoyama et al.
(43) reported that the negative inotropic effect of cardiac
contractile dysfunction was directly mediated by TNF-alpha in
the adult mammalian myocardium and that this might be
caused by decreased levels of intercellular calcium during the
systolic contraction sequence. If so, it may also be possible that
cardiac contractile dysfunction was not only caused by a
TNF-alpha–mediated NO-dependent mechanism but was also
partially due to the direct effects of TNF-alpha released from
the myocardium.
Clinical considerations and study limitations. Ventricular
contractility was found to be impaired in patients with DCM,
with a poorer prognosis for the iNOS-positive group than for
the iNOS-negative group. On the basis of this finding, it may be
possible that the progression of ventricular dysfunction and
dilation in some patients with DCM may be related to the
following pathogenetic mechanisms. The viral or autoimmune
abnormalities, or both, associated with depressed host–
defense immunity induce a continuous triggering of an im-
mune inflammatory reaction in myocardial tissue, leading to
stimulation of cytokine in cardiomyocytes. One or several of
these cytokines then induce expression of iNOS mRNA in
myocardial tissue, leading to excessive and persistent produc-
tion of NO in the myocardium. The NO derived from cytokine-
induced iNOS would then reduce cardiac contractility by virtue
of its negative inotropic properties in an autocrine or paracrine
fashion. Furthermore, because NO has cytotoxic effects, the
cardiomyocytes lost may be replaced by nonmyocytic tissue,
resulting in thinning of the ventricular wall and dilation, which
constitutes the ventricular remodeling characteristic of DCM.
This hypothesis is supported by our finding of greater abnor-
Table 3. Comparison of Clinical Characteristics of Patients With
Dilated Cardiomyopathy With and Without Inducible Nitric Oxide
Synthase Messenger Ribonucleic Acid Expression
iNOS
p Value
Positive
(n 5 13)
Negative
(n 5 11)
Age (yr) 64.8 6 8.5 50.7 6 18 0.02
M/F 9/4 10/1 0.2
NYHA
I 1 2
II 10 6 0.3
III 2 3
CTR (%) 59.0 6 5.4 57.4 6 4.9 0.5
Atrial fibrillation 6 6 0.2
ACEI therapy 6 5 0.9
BB therapy 4 3 0.5
LV end-systolic diameter (mm) 576 7 50 6 7 0.04
LV end-diastolic diameter (mm) 656 7 63 6 7 0.4
LVEF (%) 27 6 7 37 6 9 0.006
PCWP (mm Hg) 9.5 6 4 11 6 5 0.5
CI (liters/min per m2) 2.8 6 0.8 2.8 6 0.7 0.9
LV end-diastolic pressure (mm Hg) 14.16 7.0 10.6 6 5 0.17
Data presented are mean value 6 SD or number of patients. CTR 5
cardiothoracic ratio; LV 5 left ventricular; other abbreviations as in Table 1.
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mality in ventricular systolic function and left ventricular
morphology in the iNOS-positive group than in the iNOS-
negative group.
However, the present study could not establish a causal role
for iNOS in the etiology of DCM. It is clear that further studies
will be required to determine the relation between cytokine-
induced myocardial NO production and the development or
progression of left ventricular dysfunction.
This study did not examine patients with cardiac disease
due to different etiologies matched for ventricular function and
clinical severity. It therefore remains uncertain whether the
observed high incidence of iNOS mRNA expression is specific
to patients with DCM. However, preliminary research (35)
suggests that the messenger gene can be detected in the
myocardium of patients with coronary artery disease. Lewis et
al. (44) recently demonstrated that iNOS mRNA was detected
in the human cardiac allograft with associated left ventricular
contractile dysfunction. In experimental animal models of
acute myocardial infarction, iNOS activity has been reported
(45,46) to be significantly increased in the infarcted area of
myocardium (45,46). Furthermore, although it was not ascer-
tained whether the pathogenesis of DCM is directly related to
iNOS expression and TNF-alpha, these observations suggest
that myocardial coexpression of iNOS and TNF-alpha may not
only be involved in the development or progression of DCM
but may also play a much broader pathophysiologic role in
heart failure due to various etiologies.
Conclusions. The present study indicated that iNOS
mRNA was consistently coexpressed with TNF-alpha mRNA
in myocardial tissue obtained from a subgroup of patients with
DCM and advanced left ventricular dysfunction.
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